## IN THE CLAIMS

Please amend the claims as follows:

Claims 1-53 (Canceled).

Claim 54 (Previously Presented): A method of making a terminally methyl-branched iso- or anteiso-fatty acid, or a mixture of said fatty acids, which comprises culturing a bacteria strain containing said fatty acid(s) to form a fermentation solution containing said fatty acid(s), and then isolating said fatty acid(s), from the fermentation solution, wherein the bacteria strain is from the genus *Stenotrophomonas*.

Claim 55 (Previously Presented): The method of claim 54, wherein the culture medium comprises a soybean medium.

Claim 56 (Previously Presented): The method of Claim 55, wherein the soybean medium has the following formula:

Soybean	5-10 %
or soybean milk or bean cake (by soybean wt.)	5-15 %
Yeast extract	0.02-0.5 %
or yeast powder	0.02-0.5 %
CaCO <sub>3</sub>	0.05-0.25 %
K <sub>2</sub> HPO <sub>4</sub>	0.02-0.10 %
MgSO <sub>4</sub>	0.01-0.05 %
NaCl	0.01-0.04 %
$Na_2MoO_4$	5.0-30ppm
ZnSO <sub>4</sub>	2.5-15ppm

Application No. 09/647,918
Reply to Final Office Action dated November 1, 2005

CoCl<sub>2</sub>

5.0-20ppm.

Claim 57 (Canceled).

Claim 58 (Previously Presented): The method of Claim 54, wherein the bacterial strain is *Stenotrophomonas maltophilia*.

Claim 59 (Previously Presented): The method of Claim 58, wherein said bacterial strain is assigned ATCC 202105.

Claim 60 (Previously Presented): A method of making a fermentation solution containing at least one terminally methyl-branched iso- or anteiso-fatty acid, which comprises culturing a bacteria strain containing said fatty acid in a nutritive medium to form a fermentation solution containing said fatty acid, wherein the bacteria strain is from the genus *Stenotrophomonas*.

Claim 61 (Previously Presented): The method of Claim 60, wherein the nutritive medium comprising a soybean medium.

Claim 62 (Previously Presented): The method of Claim 61, wherein the soybean medium has the following formula:

Soybean 5-10 %

or soybean milk or bean cake (by soybean wt.) 5-15 %

Yeast extract 0.02-0.5 %

or yeast powder 0.02-0.5 %

CaCO <sub>3</sub>	0.05-0.25 %
K₂HPO₄	0.02-0.10 %
MgSO <sub>4</sub>	0.01-0.05 %
NaCl	0.01-0.04 %
$Na_2MoO_4$	5.0-30ppm
ZnSO <sub>4</sub>	2.5-15ppm
CoC1 <sub>2</sub>	5.0-20ppm.

Claim 63 (Canceled).

Claim 64 (Previously Presented): The method of Claim 60, wherein the bacterial strain is *Stenotrophomonas maltophilia*.

Claim 65 (Previously Presented): The method of Claim 64, wherein said bacterial strain is assigned ATCC 202105.

Claim 66 (Previously Presented): A product made by the method of Claim 60.

Claim 67 (Previously Presented): A product made by the method of Claim 61.

Claim 68 (Previously Presented): A product made by the method of Claim 62.

Claim 69 (Canceled).

Claim 70 (Previously Presented): A product made by the method of Claim 64.

Claim 71 (Previously Presented): A product made by the method of Claim 65.

Claims 72-78 (Canceled).

Claim 79 (Previously Presented): The product of Claim 66, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

Claim 80 (Previously Presented): The product of Claim 67, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

Claim 81 (Previously Presented): The product of Claim 68, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

Claim 82 (Canceled).

Claim 83 (Previously Presented): The product of Claim 70, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

Application No. 09/647,918 Reply to Final Office Action dated November 1, 2005

Claim 84 (Previously Presented): The product of Claim 71, which is in the form of a liquid, powder, capsule, tablet, injection, or encapsulated with liposome, or topically applied in the form of a cream, ointment, or lotion.

Claims 85-90 (Canceled).

Application No. 09/647,918 Reply to Final Office Action dated November 1, 2005

## **DISCUSSION OF THE AMENDMENT**

Claims 87-90 have been canceled.

No new matter has been added by the above amendment. Claims 54-56, 58-62, 64-71, 79-81, 83, and 84 are now pending in the application.